2025 ASPC Congress: CVD Prevention Highlights ICYMI
Okay, hereS a summary of the key takeaways from the provided text, focusing on the cardiovascular health updates:
Key Cardiovascular Health Updates:
- AI in Preventive Cardiology: Different forms of AI technology can be beneficial in preventive cardiology. (Link: https://www.ajmc.com/view/different-forms-of-ai-technology-can-be-beneficial-in-preventive-cardiology)
- GLP-1 Receptor Agonists & Cardiovascular Outcomes:
* GLP-1 receptor agonists significantly improved cardiovascular outcomes in patients with coronary plaque. This included lower rates of major adverse cardiovascular events, myocardial infarction, and hospitalizations, along with improved lipid levels and 1-year survival.
* In patients recovering from STEMI (heart attack), GLP-1s were associated with lower 30-day readmissions, fewer recurrent heart attacks, reduced inpatient admissions, and improved glycemic and lipid measures. (Link: https://www.ajmc.com/view/glp-1-receptor-agonists-reduce-adverse-cardiovascular-outcomes-improve-survival)
In essence,the text highlights the potential of both AI and GLP-1 receptor agonists in improving cardiovascular health and outcomes.